Profile data is unavailable for this security.
About the company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
- Revenue in CAD (TTM)0.00
- Net income in CAD-39.16m
- Incorporated2006
- Employees22.00
- LocationBriacell Therapeutics CorpSuite 300 - Bellevue Centre235 -15th StreetWEST VANCOUVER V7T 2X1CanadaCAN
- Phone+1 (604) 921-1810
- Fax+1 (604) 921-1898
- Websitehttps://briacell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avicanna Inc | 25.50m | -1.88m | 22.62m | 38.00 | -- | 6.82 | -- | 0.8873 | -0.0165 | -0.0165 | 0.2262 | 0.0264 | 1.22 | 2.89 | 10.84 | -- | -9.02 | -61.54 | -51.98 | -226.72 | 51.95 | 49.33 | -7.37 | -150.05 | 0.3804 | -- | 0.00 | -- | 51.62 | 172.88 | 58.62 | -- | -44.27 | -- |
| Principal Technologies Inc | 262.84k | -4.32m | 27.60m | -- | -- | -- | -- | 105.01 | -0.1043 | -0.1072 | 0.0063 | -0.0126 | 0.2272 | -- | 1.68 | -- | -372.16 | -- | -2,615.25 | -- | -- | -- | -1,637.81 | -- | -- | -223.78 | -- | -- | -44.22 | -- | -162.24 | -- | -- | -- |
| Thiogenesis Therapeutics Corp | 0.00 | -6.82m | 27.99m | -- | -- | 13.00 | -- | -- | -0.1439 | -0.1439 | 0.00 | 0.0415 | 0.00 | -- | -- | -- | -173.15 | -- | -216.52 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 37.87 | -- | -- | -- |
| MustGrow Biologics Corp | 7.54m | -6.37m | 30.85m | 0.00 | -- | 9.91 | -- | 4.09 | -0.1206 | -0.1206 | 0.1435 | 0.0494 | 1.45 | 5.49 | 45.16 | -- | -122.84 | -54.87 | -193.93 | -66.95 | 14.51 | -- | -84.52 | -341.26 | 1.25 | -103.31 | 0.1671 | -- | -91.55 | -- | -622.18 | -- | -- | -- |
| Resverlogix Corp | 0.00 | -9.68m | 31.57m | 18.00 | -- | -- | -- | -- | -0.0341 | -0.0341 | 0.00 | -0.4226 | 0.00 | -- | -- | 0.00 | -91.25 | -- | -- | -- | -- | -- | -- | -- | 0.0248 | -1.30 | -- | -- | -- | -- | 54.39 | -- | -- | -- |
| Microbix Biosystems Inc | 16.76m | -4.27m | 33.25m | 69.00 | -- | 1.25 | -- | 1.98 | -0.0308 | -0.0308 | 0.1205 | 0.1917 | 0.4417 | 1.09 | 3.76 | -- | -11.25 | 3.86 | -12.39 | 4.37 | 46.74 | 55.92 | -25.48 | 6.37 | 4.48 | -4.28 | 0.2051 | -- | -26.81 | 12.04 | -163.80 | -- | -0.4115 | -- |
| Briacell Therapeutics Corp | 0.00 | -39.16m | 37.68m | 22.00 | -- | 0.7192 | -- | -- | -72.69 | -72.69 | 0.00 | 7.23 | 0.00 | -- | -- | 0.00 | -246.96 | -63.88 | -359.42 | -70.71 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -449.14 | -- | -- | -- |
| ZYUS Life Sciences Corp | 465.00k | -33.74m | 46.80m | 2.00 | -- | -- | -- | 100.66 | -0.4505 | -0.4505 | 0.0062 | -0.1659 | 0.0208 | 0.3346 | 1.17 | -- | -150.55 | -74.90 | -454.68 | -102.81 | 13.12 | 3.61 | -7,256.77 | -8,974.20 | 0.0726 | -9.28 | 6.94 | -- | 37.04 | 313.06 | 20.63 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Citadel Advisors LLCas of 15 Jan 2026 | 716.70k | 11.54% |
| 3i Management LLCas of 31 Mar 2025 | 19.00k | 0.31% |
| Flagship Harbor Advisors LLCas of 31 Dec 2025 | 4.00k | 0.06% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 3.20k | 0.05% |
| Desjardins Securities, Inc.as of 31 Dec 2025 | 1.20k | 0.02% |
| UBS Securities LLCas of 31 Dec 2025 | 638.00 | 0.01% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 301.00 | 0.01% |
| Allworth Financial LPas of 31 Dec 2025 | 100.00 | 0.00% |
| RBC Capital Markets LLC (Investment Management)as of 31 Dec 2025 | 100.00 | 0.00% |
| Group One Trading LLCas of 31 Dec 2025 | 70.00 | 0.00% |
